Market Overview

UPDATE: Jefferies Reiterates Hold Rating, Raises PT on ResMed

Related RMD
Qualcomm Announces New Connected Health Collaborations at Connect 2014
UPDATE: ResMed Receives Permanent Injunction Against APEX In Germany, Continues Enforcement Of Patents in Europe

In a report published Friday, Jefferies reiterated its Hold rating on ResMed (NYSE: RMD), and raised its price target from $35.00 to $42.00.

Jefferies noted, “RMD reported strong FQ2 results with revs and EPS beating by $13mm and $0.02. The upside was across the board, albeit off favorable year ago comps. Although we have clearly missed the ride, the tailwinds of HST & cardio adoption coupled with margin benefits from mix and Shanghai manufacturing are still blowing. That said, the stock is fully valued and Round II implementation in the US remains a hard to handicap risk keeping us at Hold.”

ResMed closed on Thursday at $45.47.

Latest Ratings for RMD

DateFirmActionFromTo
Aug 2014JefferiesMaintainsHold
Jul 2014Deutsche BankDowngradesBuyHold
Jun 2014JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (RMD)

Around the Web, We're Loving...

Get Benzinga's Newsletters